Introduction: Amiodarone infusion has been recommended for life-threatening ventricular arrhythmias. However its effectiveness in Japanese patients has not yet been determined.
Introduction
Sudden cardiac death is responsible for 30,000 deaths annually in Japan and up to 350,000 deaths per year in USA. 1) Ischemic heart disease accounts for approximately 30% of these events in Japan but in USA it is responsible for more than 80% of such events. 2, 3) A variety of conditions such as arrhythmogenic right ventricular dysplasia, heart surgery, and cardiac sarcoidosis, are among the other causes of sudden cardiac death. 1, 4) The initial heart rhythm is an important factor in determining patient survival in out-of-hospital circulatory arrest. Failure to control hemodynamically unstable ventricular tachycardia (VT) or ventricular fibrillation (VF) adversely affects survival. [4] [5] [6] Amiodarone, an agent with broad antiarrhythmic activity, has produced favourable outcomes in the treatment of life-threatening relapsing arrhythmias such as VT and VF. 7) Oral amiodarone was approved for the treatment of heart arrhythmias in Japan in 1992. 8, 9) The use of oral amiodarone is challenging in emergency cases, as it may take several days to reach steady state. Intravenous (iv) amiodarone infusion is rapidly effective and can be used for the emergency treatment of life-threatening ventricular arrhythmias; its usefulness in the care of hospitalized patients has been widely demonstrated in Europe and USA. [9] [10] [11] A number of studies have been conducted in USA, including two double-blind dose-ranging studies, 11, 12) and a double-blind comparison of amiodarone and bretylium. 13) Starting in 1988, these three double-blind studies were conducted to determine the efficacy and safety of amiodarone in patients with life-threatening ventricular arrhythmias refractory to lidocaine and procainamide. At a dose of amiodarone 1050 mg/day (the approved dose in the USA), the nonrecurrence rate of hemodynamically deteriorating VT/VF at in the three studies was 40%, 41% (after 48 hours), and 53% (after 24 hours), respectively. Adverse reactions were observed in 433/814 subjects (53%) in the three studies; the adverse reaction with the highest incidence rate was decreased blood pressure. Death occurred in 353/814 subjects (43%); the most common cause was hemodynamically destabilizing VT/VF, followed by cardiogenic shock and asystole. For 34 deaths (4%), a causal relationship with the drug could not be ruled out. Based on these data, the drug was approved in USA in 1995 as an orphan drug for the following indications: initiation of treatment and prophylaxis of frequently recurring VF and VT in patients refractory to other therapy.
Intravenous amiodarone can also be used to treat patients with VT/VF in whom oral amiodarone is indicated but who are unable to take oral medication.
Randomized, double-blind studies have demonstrated the survival advantage of amiodarone over control treatment in the management of ventricular arrhythmias. The Amiodarone in the Out-of-Hospital Resuscitation of Refractory Sustained Ventricular Tachyarrhythmia (ARREST) 12) study was a randomized, double-blind, placebo-controlled study of intravenous amiodarone in patients with out-of-hospital cardiac arrest. Patients who had cardiac arrest with VF (or pulseless VT) and who had not been resuscitated after receiving three or more precordial shocks were randomly assigned to either intravenous amiodarone 300 mg (246 patients) or placebo (258 patients). There was no significant difference between the amiodarone and placebo groups in the duration of the resuscitation attempt (meanAEstandard deviation; 42 AE 16:4 and 43 AE 16:3 minutes, respectively), the number of shocks delivered (4 AE 3 and 6 AE 5, respectively), or the proportion of patients who required additional antiarrhythmic drugs after the administration of the study drug (66% and 73%, respectively). Recipients of amiodarone were more likely to survive hospital admission (44% versus 34% of the placebo group; p = 0.03). A further double-blind randomized study, Amiodarone versus Lidocaine in Prehospital Refractory Ventricular Fibrillation Evaluation (ALIVE), 12) compared intravenous lidocaine with intravenous amiodarone as an adjunct to defibrillation in 347 patients with out-ofhospital cardiac arrest. Patients resistant to three shocks, intravenous epinephrine, and a further shock and patients who had recurrent ventricular fibrillation after initially successful defibrillation were randomly assigned to intravenous amiodarone or placebo. Compared with lidocaine, amiodarone led to substantially higher rates of survival from the time of cardiac arrest to hospital admission (22.8% versus 12.0%; p = 0.009). Thus, the usefulness of iv amiodarone has been demonstrated in both hospitalized patients with cardiovascular disease and in the resuscitation patients brought to the critical care unit of hospitals.
Based on these results, the Advanced Cardiac Life Support (ACLS) Guidelines were prepared by the International Liaison Committee On Resuscitation (ILCOR) (Europe and USA) recommending iv amiodarone as first-line therapy for cardiopulmonary resuscitation.
14) In Japan, iv amiodarone was only approved recently, and very few reports of its use in the Japanese population are available. The present study was undertaken to evaluate the efficacy and safety of iv amiodarone infusion in Japanese patients with recurrent life-threatening ventricular arrhythmias. study conducted in 39 medical centers in Japan. Hospitalized patients with at least two episodes of hemodynamically unstable VT/VF within the 24-hour period prior to inclusion were treated with iv amiodarone. Hemodynamically destabilizing VT was defined as arrhythmia with systolic blood pressure <80 mmHg, or clinical signs and symptoms of shock requiring non-drug therapy to terminate the arrhythmia. Institutional review boards at each participating institution approved the study protocol. Written informed consent was obtained from each patient or their next of kin before inclusion in the trial. The study was performed in accordance with the Pharmaceutical Affairs Law and the Japanese Ministerial Ordinance on Standards for Clinical Studies of Medicines (Good Clinical Practice).
Patients
Hospitalized patients aged !20 years with !2 episodes of hemodynamically destabilizing VT or VF on the day before informed consent and in whom treatment with lidocaine, mexiletine, or procainamide was ineffective or poorly tolerated within 72 hours before giving consent were included. Exclusion criteria included: drug-induced arrhythmias or arrhythmias due to hypokalemia (potassium <3:0 mEq/L); acute pulmonary edema or cardiogenic shock (excluding that resulting from VT or VF); previous treatment with amiodarone, systolic blood pressure of <90 mmHg (excluding patients currently experiencing VT or VF); sick sinus syndrome, symptomatic bradycardia (<50 beats/minute), sinoatrial block, sinus arrest, or atrioventricular block (excluding patients with pacemaker); QT prolongation; torsades de pointes, contraindication to oral amiodarone, as suggested by the prescribing information; any patients judged by the investigator as unsuitable. There was an extremely small number of prospective subjects eligible for recruitment within the duration of the study at the limited number of medical institutions where emergency treatment facilities for life-threatening arrhythmias and fulltime physicians specialized in treating arrhythmias were available. The study was thus limited to 47 patients.
Amiodarone was administered as an initial rapid infusion of 125 mg over 10 min followed by continuous iv infusion of 50 mg/h for 6 hours (loading infusion) and then 25 mg/h for a further 42 hours (maintenance infusion). Amiodarone ampoules were diluted with 500 mL of 5% glucose solution for infusion. At the discretion of the treating physician, maintenance amiodarone (25 mg/h iv) could be continued for up to 9 days. If judged necessary, an additional rapid infusion dose of iv amiodarone (125 mg) was permitted. The maximum permitted daily amiodarone dose was 1,750 mg. Concurrent use of lidocaine and nifekalant was not allowed during the first 48 hours (evaluation period).
After iv amiodarone, treatment could be switched to oral amiodarone, according to the judgment of the treating physician. A final follow-up visit was performed at 1 month, which included 12-lead electrocardiogram (ECG), physical examination, chest X-ray, laboratory parameters, and assessment of the blood concentration of amiodarone. At that time the physician assessed the control of arrhythmia as either ''good'' or ''poor.'' Given the seriousness of the indication and the small size of the target population, this study was designed as an uncontrolled study involving one subject group in order to accumulate as much efficacy and safety data on Japanese patients as possible.
Assessment of amiodarone serum concentration
For patients who received amiodarone per protocol with no additional doses, serum amiodarone concentrations were measured at 10 and 30 min, and 1, 6, 12, 24, and 48 hours after the start of dosing by high performance liquid chromatography.
15)

Evaluation criteria
The primary endpoint for efficacy was the proportion of patients free from hemodynamically unstable VT or VF at 48 hours, estimated according to the Kaplan-Meier method. Secondary endpoints included: frequency of hemodynamically destabilizing VT or VF; proportion of patients free from failure events (including relapse of VT/VF and drug discontinuation); and treatment outcome based on physician evaluation at 1 month. Safety was assessed using laboratory tests, physical examinations, 12-lead ECG, and chest X-ray. Adverse events were defined as severe if they resulted in discontinuation of amiodarone infusion, death or disability of the patient, or if the events had the potential to cause death or disability.
Statistical considerations
The Kaplan-Meier method was used to determine the proportion of patients free from hemodynamically destabilizing VT or VF at 48-hour, in order to estimate the efficacy based on non-recurrence rate of VT/VF. Kaplan-Meier plots were also used to show the changes in the non-recurrence rate of hemodynamically destabilizing VT/VF within 48 hours.
As so few prospective subjects meeting the inclusion criteria were recruited in emergency treat-ment facilities for life-threatening arrhythmias, it was assumed that an estimated 48-hour non-recurrence rate of 40%, with the 95% confidence interval (CI) not crossing below 20%, would be sufficient to demonstrate that amiodarone provided a meaningful clinical benefit. Forty-seven patients were required to detect the 48-hour event-free survival rate. Patient backgrounds and other factors that may affect the results were also analyzed.
Results
From January 16, 2003 to December 16, 2004 , 47 patients were enrolled and examined in this study. Relevant demographic and clinical data are shown in Table 1 . Four patients were found to be ineligible (inclusion criteria not met), one patient died during the initial rapid infusion stage, and for one patient it was not possible to acquire valid data during the first 48-hour period of the study. Hence, 41 patients were evaluated for efficacy; safety was evaluated for all 47 patients. Presenting arrhythmias included VT, VF, and VT plus VF and all patients had underlying cardiac disorder ( Table 1) .
Efficacy
Among the 41 patients analyzed for efficacy, the proportion of patients free from hemodynamically unstable VT or VF estimated by the Kaplan-Meier method was 72.1% at 6-hour after the end of the rapid infusion (95% CI: 58.0-86.1%), 64.3% at 12-hour (49.3-79.3%), 56.6% at 24-hour (41.1-72.2%), and 53.9% at 48-hour (38.2-69.6%) (Figure 1) . Relapse of hemodynamically destabilizing VT/VF most often occurred during the first 24 hours of treatment. The mean AE standard deviation of hemodynamically destabilizing VT/VF throughout the efficacy evaluation period was 0:36 AE 1:1 episodes/ hour.
All VT/VF episodes and treatment discontinuations were considered as failure events. The proportion of patients remaining event-free was 68.3% at 6-hour (95% CI: 51.9-81.9%), 61.0% at 12-hour (44.5-75.8%), 51.2% at 24-hour (35.1-67.1%), and 48.8% at 48-hour (32.9-64.9%) (Figure 2) .
One patient died during the initial treatment period and one patient had no efficacy data within 48 hours of initial rapid infusion. These patients did not receive a 1 month follow up. Arrhythmias remained well controlled in 82.4% of surviving patients in the evaluable population, which was similar to the result in the safety population (83.8%) ( Table 2) . Table 3 shows the results of stratified analysis of the proportion of patients free from hemodynamically destabilizing VT or VF. This proportion was higher for patients with LVEF !30% than for patients with LVEF <30%. The proportion of female patients (2 of 14) who suffered relapse of VT/VF was higher than in males. However, when cardiac function was analyzed separately in males and females, only 11 of the 27 men (40.7%) had favorable cardiac function compared with 10 of the 14 women (71.4%).
Safety
All patients had at least one adverse event related to their underlying cardiac condition. During the 48-hour loading and maintenance period, treatment was discontinued by the investigator in 4 patients due to adverse events. These four events were: QTc prolongation (n ¼ 2), fall in blood pressure (n ¼ 1), and low cardiac output syndrome (n ¼ 1).
During the 1-month follow-up period, 7 of the 41 patients (17.1%) included in the efficacy evaluation and 8 of the 47 (17.0%) patients included in the safety evaluation died while 7 patients (14.9%) enrolled in the study developed severe adverse events for which a causal relationship with the investigational product could not be ruled out ( Table 4) . The eight deaths were due to VT/VF (n ¼ 3), sepsis (n ¼ 2), cardiogenic shock (n ¼ 1), myocardial rupture (n ¼ 1), and respiratory failure (n ¼ 1). The majority of deaths were due to underlying cardiac disease. In the two cases of sepsis, both patients had been hospitalized for infection before study entry. Among the 7 patients with severe adverse events, 6 experienced severe cardiovascular adverse reactions, including prolongation of QTc interval, bradycardia, VT/VF, hypotension, and low cardiac output syndrome. The seventh patient experienced a severe non-cardiovascular adverse reaction: liver function disorder (elevated serum transaminase twice the upper limit of normal). In this patient, almost 1 month after the study infusion was stopped, glutamyl oxaloacetic transaminase increased to 1400 units and glutamyl pyruvic transaminase had increased to 715 units. Hepatic enzymes slowly returned to normal over 3 weeks. Failure events includes all the VT/VF-relapse and discontinuation of the treatment. Interstitial lung disease, pulmonary fibrosis, and corneal pigmentation-known adverse reactions with oral amiodarone treatment-were not reported in this study. One case of mild hypothyroidism, as defined by the investigator, was seen. Neither torsades de pointes nor bundle-branch block were observed.
Thirty-six and 17 of 47 subjects showed abnormalities in QRS and QT, respectively. A mild QTc prolongation was seen in 8 (30-60 ms) and in 19 (>60 ms) of 47 subjects.
Serum amiodarone levels Figure 3 shows the serum amiodarone concentrations for the 5 patients who did not receive any additional doses of amiodarone that were allowed by the protocol. They received the initial rapid, loading, and maintenance infusions. In these cases, serum amiodarone levels rose quickly after the start of the rapid infusion and remained within the effective range (1.0-2.5 mg/mL) from 30 min to 48-hour after the start of dosing. The remaining patients were given doses of other antiarrhythmic agents or additional doses of amiodarone at the discretion of the investigator. These patients were thus excluded from the analysis of serum amiodarone levels in this report.
Discussion
Amiodarone injection is the only antiarrhythmic drug whose efficacy against life-threatening arrhythmias has been demonstrated in prospective, randomized, double-blind studies at critical care units. 12, 13) However its effectiveness as an iv therapy has not previously been examined in Japanese patients. In the present study, 39 of the 41 patients included in the efficacy evaluation had not responded to previous treatment with lidocaine or mexiletine, and 4 of these 41 patients had not responded to procainamide. Thirteen of the 41 patients were switched from nifekalant therapy to amiodarone because the former treatment did not provide adequate relapse prevention. Amiodarone was effective in preventing relapse of VT/VF in 5 of these 13 patients.
The results of this study confirm that iv amiodarone is effective for the prevention of hemodynamically destabilizing VT or VF in Japanese patients. The proportion of patients free from hemodynamically destabilizing VT or VF 6 hours after the end of the rapid infusion was 72.1% and at 48-hour 53.9% of patients were still relapse free. Relapse of VT/VF most often occurred during the first 24 hours of treatment. Severe adverse reactions to amiodarone were seen with the iv route in 8 of the 47 patients, but these were adequately dealt with using clinical measures. Although 8 patients died during the follow-up period, these deaths were associated with the severity of the underlying disease and were not attributed to amiodarone. Given the severity of the patients' conditions and the urgent need for treatment, the safety of amiodarone can be considered as acceptable.
The dose levels of amiodarone used in this study were based on data from a dose-determination study conducted in USA after taking into account the difference in body weight between Americans and Table 4 Severe adverse reactions (adverse events whose causal relationship to the investigational drug could not be ruled out).
Event
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Japanese. [16] [17] [18] The present study in Japanese patients demonstrated that a rapid infusion of amiodarone resulted in a quick increase in serum amiodarone levels, which then remained within the therapeutically effective range by means of maintenance infusions.
The proportion of patients free from hemodynamically destabilizing VT or VF during the 48-hour observation period and the proportion of patients free from all failure events during the same period were compatible with those reported by investigators outside of Japan. [16] [17] [18] Amiodarone administered via the iv route is thus effective in preventing recurrence of VT or VF.
The stratified analysis in Table 3 revealed a difference in the proportion of VT/VF-free cases between males and females, but this difference seems to be attributable to the small sample size rather than to a marked gender-related difference in cardiac function. It therefore seems reasonable to suggest that iv amiodarone is equally efficacious in both men and women.
Until recently, the only available agents in Japan for the treatment of life-threatening ventricular arrhythmias were lidocaine, procainamide, mexiletine, and nifekalant. Reports on the utility of lidocaine are sparse and some investigators suggest that lidocaine elevates the threshold for defibrillation. 19) Procainamide is sometimes used in lidocaineresistant cases, but it is likely to decrease blood pressure. The prominence of both lidocaine and procainamide in cardiopulmonary resuscitation guidelines has been decreasing in recent years. 20) Nifekalant is a Class III antiarrhythmic agent that has been developed and approved for clinical use in Japan. It is considered to lower the threshold for VF and has little effect or only a mild positive inotropic effect on myocardial contractility. In a retrospective study of 120 patients with cardiac arrest with VF that persisted after 3 shocks from an external defibrillator, lidocaine and nifekalant were compared for short-term survival. Nifekalant was associated with significantly higher rates of survival after hospital admission (67% versus 37%, p < 0:001) and 24-hour survival (53% versus 31%, p ¼ 0:01).
21) There were some limitations to this study: it was retrospective and was not designed as a controlled clinical trial, because patients who had previously received lidocaine served as control. The baseline clinical characteristics showed a lower dose of epinephrine was used in the nifekalant group than for the controls.
Lidocaine and nifekalant were used during different periods and thus the outcomes may have been affected by factors such as technical advances and improved medical care.
There is little evidence of the efficacy of nifekalant in the management of cardiac arrest. In a study of 91 cases of VT/VF resistant to a single dose of lidocaine followed by DC shock, patients were divided into two groups. In the first group, nifekalant was used (0.15-0.3 mg/kg) and DC shocks were administered. In the second group, additional lidocaine was given up to a maximum of 3 mg/kg in combination with DC shock. Sinus rhythm was restored in 43% of the non-nifekalant group and in 81% of the nifekalant group. The defibrillation rate was higher in the nifekalant group than for lidocaine alone and the VT/VF rate reduction effect could be maintained even with acidosis. However, sinus bradycardia, and torsades de pointes were occasionally observed with nifekalant therapy. 22) Regarding safety parameters, all of the 47 patients developed at least one treatment-emergent adverse event and 8 patients died during the 1-month followup period. Causal relationship to the drug was ruled out for all cases of death. Severe adverse events were noted in 18 patients for whom a relationship to amiodarone could not be excluded in 7 patients. Severe adverse reactions include cardiac disorders (6 patients), laboratory finding abnormalities (2 patients), and an administration to hospital (1 patient). All of the adverse reactions observed in this study have been previously described with oral amiodarone in Japan and iv amiodarone in other countries. Interstitial pulmonary diseases, a known adverse event with long-term oral amiodarone therapy, were not reported in the present study. QTc interval was prolonged in 27 patients but torsades de pointes was not observed and no bundle-branch block was recorded. An increase in QT interval is linked to the pharmacologic effect of amiodarone.
The purpose of this study was to evaluate the efficacy of amiodarone for the management of VT/ VF. We did not use a control arm, as amiodarone iv is indicated for severely ill patients who require urgent treatment. We demonstrated the effectiveness of amiodarone as 53.9% of patients were free of recurrence at 48-hour. Efficacy of amiodarone in terms of the proportion of patients free from VT or VF and the proportion of failure-free cases in this study was comparable with or higher than that of both the amiodarone group and placebo groups as reported in studies conducted in Europe and USA, and the safety of the drug was within an acceptable range. The results of this study demonstrate the great utility of amiodarone via the iv route as a means of preventing life-threatening ventricular arrhythmias in Japanese patients. Limitations of the present study were a protocol which did not include a control and the small number of patients enrolled in the study. Therefore we must exercise care in interpreting the results of this study.
